CA 19-9 antibody, a carbohydrate antigenic determinant identified as a sialylated lacto-N-fucopentose II, is related to the Lewis blood group. CA 19-9 might play a role in the process of tumor progression as an adhesion molecule. The CA 19-9 antibody has been shown to label adenocarcinomas of the pancreas, stomach, breast, colon and gall bladder. CA 19-9 is also expressed in primary and metastatic ovarian carcinomas. Studies show that CA 19-9 positive expression may be a predictor of increased cancer mortality.
1. Kelly PJ, et al. J Clin Pathol. 2010 Feb; 63(2):169-73.
2. Nakao A, et al. Semin Surg Oncol. 1998 Jul-Aug; 15(1):15-22.
3. Nakayama T, et al. J Surg Oncol. 1997 Dec; 66(4):238-43.